Percutaneous transluminal angioplasty for peripheral artery disease confers cardiorenal protection

Journal of Human Hypertension

Volumn 28, Issue 1, 2014, Pages 51-55

  Eguchi, K ^a   Murakami, A ^b   Horaguchi, T ^b   Kato, M ^b   Miyashita, H ^a   Kario, K ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b International University of Health and Welfare   (Japan)

Author keywords

Augmentation index; Left ventricular mass index; Percutaneous transluminal angioplasty; Peripheral artery disease; Urinary albumin excretion ratio

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; CILOSTAZOL; DIURETIC AGENT; SARPOGRELATE;

ADD ON THERAPY; AGED; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE MASS; HEART PROTECTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; ALBUMINURIA; ANGIOPLASTY; CARDIOVASCULAR DISEASES; COMORBIDITY; ECHOGRAPHY; KIDNEY DISEASES; PERIPHERAL ARTERIAL DISEASE; RISK FACTOR; TREATMENT OUTCOME;

AGED; ALBUMINURIA; ANGIOPLASTY; ANKLE BRACHIAL INDEX; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HUMANS; KIDNEY DISEASES; MALE; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84889659060     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.37     Document Type: Article

References (27)

1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Trans Atlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113(11): e463-e465.
2. Welten GM, Schouten O, Hoeks SE, Chonchol M, Vidakovic R, van Domburg RT et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 2008; 51(16): 1588-1596.
3. Meves SH, Diehm C, Berger K, Pittrow D, Trampisch HJ, Burghaus I et al. Peripheral arterial disease as an independent predictor for excess stroke morbidity and mortality in primary-care patients: 5-year results of the getABI study. Cerebrovasc Dis 2010; 29(6): 546-554.
4. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996; 25(6): 1172-1181.
5. Zheng ZJ, Sharrett AR, Chambless LE, Rosamond WD, Nieto FJ, Sheps DS et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 1997; 131(1): 115-125.
6. Ankle Brachial Index Collaboration. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008; 300(2): 197-208.
7. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97(1): 48-54.
8. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45(2): 198-202.
9. O'Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 2007; 50(1): 1-13.
10. Fu W, Ye C, Mei C, Rong S, Wang W. Reverse correlation between ankle-brachial index and left ventricular hypertrophy in patients on maintenance haemodialysis. Nephrology 2006; 11(1): 9-14.
11. Matsushita M, Nishikimi N, Sakurai T, Yano T, Nimura Y. Urinary microalbumin as a marker for intermittent claudication. Eur J Vasc Endovasc Surg 1996; 11(4): 421-424.
12. Matsui Y, Eguchi K, Shibasaki S, Ishikawa J, Hoshide S, Pickering TG et al. Monitoring of the central pulse pressure is useful for detecting cardiac overload during antiadrenergic treatment: the Japan Morning Surge 1 study. J Hypertens 2008; 26(10): 1928-1934.
13. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
14. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108(17): 2154-2169.
15. Association AD. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34(Suppl 1): S11-S61.
16. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32(1): 3-107.
17. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983; 17(1): 45-56.
18. Miyazaki M, Higashi Y, Goto C, Chayama K, Yoshizumi M, Sanada H et al. Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease. J Cardiovasc Pharmacol 2007; 49(4): 221-227.
19. Saba PS, Roman MJ, Pini R, Spitzer M, Ganau A, Devereux RB. Relation of arterial pressure waveform to left ventricular and carotid anatomy in normotensive subjects. J Am Coll Cardiol 1993; 22(7): 1873-1880.
20. Segers P, Rietzschel ER, De Buyzere ML, De Bacquer D, Van Bortel LM, De Backer G et al. Assessment of pressure wave reflection: getting the timing right! Physiol Meas 2007; 28: 91045-56.
21. O'Rourke MF, Nichols WW, Mitchell GF, Parise H, Benjamin EJ, Larson MG et al. Changes in wave reflection with advancing age in normal subjects response. Hypertension 2004; 44(6): e10-e11.
22. Westerhof BE, van den Wijngaard JP, Murgo JP, Westerhof N. Location of a reflection site is elusive: consequences for the calculation of aortic pulse wave velocity. Hypertension 2008; 52(3): 478-483.
23. Hashimoto J, Westerhof BE, Westerhof N, Imai Y, O'Rourke MF. Different role of wave reflection magnitude and timing on left ventricular mass reduction during antihypertensive treatment. J Hypertens 2008; 26(5): 1017-1024.
24. Dunn FG, Ventura HO, Messerli FH, Kobrin I, Frohlich ED. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation 1987; 76(2): 254-258.
25. Mayet J, Ariff B, Wasan B, Chapman N, Shahi M, Poulter NR et al. Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy. Hypertension 2000; 36(5): 755-759.
26. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005; 46(1): 200-204.
27. Fesler P, du Cailar G, Ribstein J, Mimran A. Glomerular hemodynamics and arterial function in normal individuals. J Hypertens 2010; 28(12): 2462-2467.